MGNX News and Press, MacroGenics Inc. From 11/28/23

2023-11-28 11:56:40 ET More on SPDR S&P 500 ETF Trust: 2024 Analyst Outlook: Mott Capital On Market Volatility, The Fed, And Investor Challenges And Opportunities The Week On Wall Street: Holiday Edition Broad Turn In Weekly Momentum Bodes Well For Stocks ...

2023-11-07 12:51:35 ET Gainers: PaxMedica ( PXMD ) +78% . Jaguar Global Growth Corp I ( JGGC ) +62% . Transmedics Group ( TMDX ) +54% . Baiyu Holdings ( BYU ) +48% . Fathom Digital Manufacturing Corporation ( FATH ) +46% . Ko...

2023-11-07 01:15:42 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q3 2023 Earnings Call Nov 06, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q3 2023 Earnings Call Transcript

2023-11-07 00:20:24 ET MacroGenics, Inc. (MGNX) Q3 2023 Earnings Conference Call November 6, 2023 16:30 ET Company Participants Scott Koenig - President and Chief Executive Officer Jim Karrels - Senior Vice President and Chief Financial Officer Conference Call ...

2023-11-06 17:13:37 ET More on MacroGenics MacroGenics' Undervalued Potential In Oncology Therapeutics MacroGenics 2023 Q2 - Results - Earnings Call Presentation MacroGenics Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on MacroGenics ...

2023-11-06 16:08:57 ET More on MacroGenics MacroGenics' Undervalued Potential In Oncology Therapeutics MacroGenics, Inc. 2023 Q2 - Results - Earnings Call Presentation MacroGenics, Inc. (MGNX) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rati...

Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of schedule Initiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., N...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

MacroGenics Inc. (MGNX) is expected to report $-0.03 for Q3 2023

ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial r...